Actinide Series Metal (at. No. 89+) Patents (Class 534/11)
-
Patent number: 5801229Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.Type: GrantFiled: September 13, 1996Date of Patent: September 1, 1998Assignee: The Board of Regents, University of Texas SystemInventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi, Vladimir A. Kral
-
Patent number: 5792881Abstract: The invention relates to hydrolyzable and polyadditive silanes, a method of heir production and of their use in the production of (hetero) silicic acid polycondensates and of polyadducts. The silanes in accordance with the invention have the general formula?(HS--R.sup.5).sub.n R.sup.6 --S--E--R.sup.5 !.sub.a SiX.sub.x R.sup.3.sub.4-a-x (I)in which the groups and indices are equal or different and have the following meaning:E=--CO--NH--, CS--NH--, --CH.sub.2 --CH.sub.2 -- or --CH.sub.2 --CH(OH)--;R.sup.3 =alkyl, alkenyl, aryl, alkylaryl or arylalkyl each with 1 to 15 carbon atoms, whereby these groups may be interrupted by oxygen or sulfur atoms, by ester, carbonyl, amide or amino groups;R.sup.5 =Alkene, arylene, arylenealkene or arylenealkene each with 1 to 15 carbon atoms, whereby these groups may be interrupted by oxygen or sulfur atoms, by ester, carbonyl, amide or amino groups;R.sup.Type: GrantFiled: March 5, 1997Date of Patent: August 11, 1998Assignee: Fraunhofer-Gesellschaft zur Forderung der angewandten Forschung e.V.Inventors: Herbert Wolter, Werner Storch
-
Patent number: 5789586Abstract: A method for preparing functionalized derivatives of organic or inorganic compounds and tetrapyrrolic compounds in particular, all of which compounds have at least one sulfonic acid group, by first preparing a sulfonyl halide intermediate of the compound then reacting the intermediate with a second compound having a reactive hydroxyl or amine group to yield the desired sulfonylamide or sulfonic esters thereof. The method may be used to produce a variety of photosensitive compounds having different functionality. For example, sulfonamide or sulfonic ester reaction products of the tetrapyrrolic compounds or other photosensitive organic molecules may exhibit an enhanced ability to localize at a particular target site for phototherapy.Type: GrantFiled: July 7, 1997Date of Patent: August 4, 1998Assignee: PDT Pharmaceuticals, Inc.Inventor: Byron Robinson
-
Patent number: 5733903Abstract: The present invention relates to the use of water-soluble texaphyrin-diamagnetic metal complexes retaining lipophilicity as photosensitizers in the treatment of benign and malignant neoplastic tissue.Type: GrantFiled: July 10, 1996Date of Patent: March 31, 1998Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Gregory W. Hemmi, Tarak D. Mody
-
Patent number: 5717076Abstract: There are provided a derivative of a metal-encapsulated fullerene having application as a functional material, superconducting material, electronics material or pharmaceutical material, and a method of synthesizing this derivative. The derivative of a metal-encapsulated fullerene having the following structure is synthesized by adding a substituted diazomethane to a metal-encapsulated fullerene and denitrifying in a solvent.Type: GrantFiled: September 10, 1996Date of Patent: February 10, 1998Assignee: Doryokuro Kakunenryo Kaihatsu JigyodanInventors: Kazunori Yamamoto, Hideyuki Funasaka, Takeshi Takahashi, Toshiyasu Suzuki, Yusei Maruyama, Tatsuhisa Kato, Takeshi Akasaka
-
Patent number: 5679814Abstract: Metallocenes, such as silicon bridged ansa-metallocenes, are purified by heating a slurry of the metallocene at elevated temperature in an aprotic, polar solvent so as to extract impurities from the metallocene into the solvent and then separating the impurity containing solvent from the metallocene.Type: GrantFiled: December 11, 1995Date of Patent: October 21, 1997Assignee: Albemarle CorporationInventors: Jamie R. Strickler, John M. Power
-
Patent number: 5658494Abstract: Novel compounds obtainable by reacting together an imido-reagent such as diphenylphosphonimido-triphenylphosphorane), or a phosphine oxide such as p-tolyldiphenylphosphine oxide, with a chelate of a transition or lanthanide or actinide metal, such as tris(dibenzoylmethide)europium III, have the property of fluorescing in UV radiation. The invention includes solid polymer bodies containing such compounds, or chelates of transition or lanthanide or actinide metals generally, the bodies having the property of emitting light or infra-red radiation when subjected to a flux of ultra-violet or ionising radiation by virtue of internally generated, e.g. by tritium ionising radiation. The body is preferably of polystyrene formed by polymerising the monomer in the presence of the compound or metal chelate.Type: GrantFiled: May 22, 1995Date of Patent: August 19, 1997Assignee: Amersham International plcInventors: Colin David Bell, John Hewer Coles Howse, Nigel Bosworth, David Martin James
-
Patent number: 5635158Abstract: The peptides described are modified with the phosphine group and are useful for marking with .sup.99m Tc and .sup.186-188 Re or paramagnetic agents for use in diagnosis and radiotherapy; in particular chelating compounds having the co-ordinating sets PN.sub.2 X, where X is --S, --O, COO--, PN.sub.3, P.sub.2 N.sub.3 and P.sub.2 N.sub.2 are described.Type: GrantFiled: June 23, 1995Date of Patent: June 3, 1997Assignee: Sorin Radiofarmaci SRLInventors: Ulderico Mazzi, Fabio Lunghi
-
Patent number: 5633354Abstract: The invention is directed to a method of incorporating expanded porphyrins, and particularly of incorporating a sapphyrin or a texaphyrin, before, during, or after chemical synthesis of an oligomer to form an expanded porphyrin-oligonucleotide conjugate, and particularly a sapphyrin- or texaphyrin-oligonucleotide conjugate. This method includes reacting derivatized nucleotides and a sapphyrin or a texaphyrin in a desired order in an automated or manual DNA synthesizer having a solid support to form a sapphyrin- or a texaphyrin-oligonucleotide conjugate.Type: GrantFiled: March 13, 1996Date of Patent: May 27, 1997Assignees: Pharmacyclics, Inc., Board of Regents, The University of TexasInventors: Darren Magda, Jonathan L. Sessler, Brent L. Iverson, Petra I. Sansom, Shaun P. Crofts
-
Patent number: 5599928Abstract: Texaphyrin metal complexes having improved functionalization include the addition of electron-donating groups to positions 2, 7, 12, 15, 18 and/or 21 and/or the addition of electron-withdrawing groups to positions 15 and/or 18 of the macrocycle. Electron-donating groups at positions 2, 7, 12, 15, 18 and/or 21 contribute electrons to the aromatic .pi. system of the macrocycle which stabilizes the metal complex to demetallation and the imine bonds to hydrolysis. The addition of substituents to the 12 and 21 positions of the macrocycle offer steric protection for the imine bonds against possible in vivo enzyme hydrolysis. Electron-withdrawing groups at positions 15 and/or 18 render the macrocycle more readily reduced, i.e. the redox potential is lower and the macrocycle more readily gains an electron to form a radical. Such texaphyrins having a low redox potential and imine bond stabilization are useful in a variety of applications.Type: GrantFiled: June 2, 1995Date of Patent: February 4, 1997Assignees: Pharmacyclics, Inc., Board of Regents, The University of Texas SystemInventors: Gregory W. Hemmi, Jonathan L. Sessler, Tarak D. Mody
-
Patent number: 5594080Abstract: This invention is directed to novel catalysts the structure and activity of which can be controlled to produce a wide range of alpha olefin polymers and co-polymers, and preferably for the production of stereoblock poly alpha olefins comprising a wide range of preselected amorphous and crystalline segments for precise control of the physical properties thereof, principally elastomeric thermoplastic properties. More specifically, this invention is directed to novel catalysts and catalysts systems for producing stereoblock polypropylene comprising alternating isotactic and atactic diastereosequences, which result in a wide range of elastomeric properties. The amount and numbers of crystalline sections, the isotactic pentad content, the number and length of intermediate atactic chains and overall molecular weight are all controllable by the steric structure of the catalysts and the process conditions.Type: GrantFiled: March 24, 1994Date of Patent: January 14, 1997Assignee: Leland Stanford, Jr. UniversityInventors: Robert M. Waymouth, Geoffrey W. Coates, Elisabeth M. Hauptman
-
Patent number: 5587371Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.Type: GrantFiled: June 2, 1995Date of Patent: December 24, 1996Assignees: Pharmacyclics, Inc., Board of Trustees, Univ. of TX Sys.Inventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi, Vladimir A. Kr al, Darren Magda
-
Patent number: 5587463Abstract: The present invention involves a novel tripyrrole dimethine-derived "expanded porphyrin" (texaphyrin), the synthesis of such compounds, their analogs or derivatives and their uses. These expanded porphyrin-like macrocycles are efficient chelators of divalent and trivalent metal ions. Metal complexes of these compounds are active as photosensitizers for the generation of singlet oxygen and thus potentially for inactivation or destruction of human immunodeficiency virus (HIV-1), mononuclear or other cells infected with such virus and tumor cells as well. A variety of texaphyrin derivatives have been produced and many more are readily obtainable. Various metal (e.g., transition, main group, and lanthanide) complexes with the texaphyrin and texaphyrin derivatives of the present invention have unusual water solubility and stability which render them particularly useful. These metallotexaphyrin complexes have optical properties making them unique as compared to existing porphyrin-like or other macrocycles.Type: GrantFiled: March 8, 1994Date of Patent: December 24, 1996Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Gregory W. Hemmi, Toshiaki Murai
-
Patent number: 5580543Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.Type: GrantFiled: June 2, 1995Date of Patent: December 3, 1996Assignees: Pharmacyclics, Inc., Board of Regents, Univ. of Texas Sys.Inventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi, Vladimir A. Kr al, Darren Magda
-
Patent number: 5569746Abstract: A process for making a metallocene, said process comprising the steps of (a) reacting an alkylsubstituted cyclopentadiene ligand, which contains a mixture of endo- and exo-isomers, with up to about a 10% excess over a stoichiometric amount of a deprotonation agent based on the amount of endo-isomers, so as to form a salt of said endo-isomers, (b) reacting the endo-isomer salt with a transition or actinide metal compound so as to form said metallocene and (c) optionally separating said exo-isomers and trace amounts of unreacted endo-isomers from said metallocene by distillation.Type: GrantFiled: January 23, 1995Date of Patent: October 29, 1996Assignee: Albemarle CorporationInventors: John Y. Lee, Edward A. Burt
-
Patent number: 5569759Abstract: The present invention involves water soluble hydroxy-substituted texaphyrins retaining lipophilicity, the synthesis of such compounds and their uses. These expanded porphyrin-like macrocycles are efficient chelators of divalent and trivalent metal ions. Various metal (e.g., transition, main group, and lanthanide) complexes of the hydroxy-substituted texaphyrin derivatives of the present invention have unusual water solubility and stability. They absorb light strongly in a physiologically important region (i.e. 690-880 nm). They have enhanced relaxivity and therefore are useful in magnetic resonance imaging. They form long-lived triplet states in high yield and act as photosensitizers for the generation of singlet oxygen. Thus, they are useful for inactivation or destruction of enveloped viruses, mononuclear or other cells infected with such viruses as well as tumor cells.Type: GrantFiled: July 28, 1993Date of Patent: October 29, 1996Assignee: Board of Regents, University of Texas SystemInventors: Jonathan L. Sessler, Gregory W. Hemmi, Tarak D. Mody
-
Patent number: 5565552Abstract: The invention is directed to a method of incorporating expanded porphyrins, and particularly of incorporating a sapphyrin or a texaphyrin, before, during, or after chemical synthesis of an oligomer to form an expanded porphyrin-oligonucleotide conjugate, and particularly a sapphyrin- or texaphyrin-oligonucleotide conjugate. This method includes reacting derivatized nucleotides and a sapphyrin or a texaphyrin in a desired order in an automated or manual DNA synthesizer having a solid support to form a sapphyrin- or a texaphyrin-oligonucleotide conjugate.Type: GrantFiled: June 7, 1995Date of Patent: October 15, 1996Assignees: Pharmacyclics, Inc., Board of Regents, Univ. of Texas Sys.Inventors: Darren Magda, Jonathan L. Sessler, Brent L. Iverson, Petra I. Sansom, Shaun P. Crofts
-
Patent number: 5559207Abstract: A method of phosphate ester hydrolysis including incubating a solution of an aqueous phosphate ester with a texaphyrin metal complex. The metal is a metal cation having catalytic activity for ester bond hydrolysis in aqueous solution, in particular, a lanthanide metal cation, preferably Eu(III) or Dy(III). A preferred substrate is RNA and a preferred texaphyrin is a derivatized texaphyrin having binding specificity, in particular, a texaphyrin covalently coupled to a site-directed molecule, preferably an oligonucleotide.Type: GrantFiled: April 14, 1994Date of Patent: September 24, 1996Assignees: Board of Regents, University of Texas, Pharmacyclics, Inc.Inventors: Jonathan L. Sessler, Daniel A. Smith, Richard A. Miller, Kevin L. Ross, Meredith Wright, William C. Dow, Vladimir A. Kr al, Brent Iverson, Darren Magda
-
Patent number: 5556997Abstract: Chiral metallocenes are prepared by reacting a salt of an asymmetric bis(cyclopentadienyl) moiety containing ligand with a chelate diamine adduct of a transition, lanthanide, or actinide metal halide in an organic solvent medium so as to produce said chiral metallocene.Type: GrantFiled: April 24, 1995Date of Patent: September 17, 1996Assignee: Albemarle CorporationInventors: Jamie R. Strickler, John M. Power
-
Patent number: 5512559Abstract: Purified imines of porphyrins, chlorins, bateriochlorins, chlorophylls, bacteriochlorophylls, purpurins, reduced purpurins, verdins, Diels Alder adducts, benzochlorins and metal complexes of the foregoing imines are disclosed. The formulas of the benzochlorinimines and of the benzochlorinimine metal complexes are set forth below: ##STR1## In specific examples, M in the metal complexes is a copper cation that is complexed with two of the nitrogens of the benzochlorinimine R' and R"" are methyl, and R1 through R8 are ethyl.Type: GrantFiled: January 19, 1995Date of Patent: April 30, 1996Assignee: The University of Toledo and Medical College of OhioInventors: Dimitris Skalkos, Steven H. Selman, James A. Hampton
-
Patent number: 5475104Abstract: The present invention involves water soluble hydroxy-substituted texaphyrins retaining lipophilicity, the synthesis of such compounds and their uses. These expanded porphyrin-like macrocycles are efficient chelators of divalent and trivalent metal ions. Various metal (e.g., transition, main group, and lanthanide) complexes of the hydroxy-substituted texaphyrin derivatives of the present invention have unusual water solubility and stability. They absorb light strongly in a physiologically important region (i.e. 690-880 nm). They have enhanced relaxivity and therefore are useful in magnetic resonance imaging. They form long-lived triplet states in high yield and act as photosensitizers for the generation of singlet oxygen. Thus, they are useful for inactivation or destruction of human immunodeficiency virus (HIV-1), mononuclear or other cells infected with such virus as well as tumor cells.Type: GrantFiled: August 25, 1993Date of Patent: December 12, 1995Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Gregory W. Hemmi, Tarak D. Mody
-
Patent number: 5457183Abstract: A method of using texaphyrins as radiosensitizers. Advantageous properties of texaphyrins for use as a radiosensitizer include i) a low redox potential which allows radiation induced solvated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing the hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical which, nevertheless, reacts readily to covalently modify neighboring molecules causing further cellular damage, and iii) intrinsic biolocalization and indifference to the presence of O.sub.2 which allow texaphyrin to be particularly effective for treating the hypoxic areas of solid tumors. Sensitizer enhancement ratios of 1.62 and 2.2 were achieved at 20 .mu.M and 80 .mu.M gadolinium-texaphyrin, respectively, with a mouse leukemia cell line.Type: GrantFiled: October 12, 1993Date of Patent: October 10, 1995Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi, Vladimir Kral
-
Patent number: 5455333Abstract: Metallocenes which are useful as olefin polymerization catalysts are prepared by reacting a compound of a metal of the group 4 to 10, lanthanide or actinide series of the Periodic Table of the Elements with a magnesium halide salt of a cyclopentadienyl containing ligand in the presence of an organic halide so as to form the metallocene while simultaneously raising the oxidation state of the metal.Type: GrantFiled: August 16, 1993Date of Patent: October 3, 1995Assignee: Albemarle CorporationInventors: Jamie R. Strickler, John M. Power
-
Patent number: 5451576Abstract: The present invention involves water soluble hydroxy-substituted texaphyrins retaining lipophilicity, the synthesis of such compounds and their uses. These expanded porphyrin-like macrocycles are efficient chelators of divalent and trivalent metal ions. Various metal (e.g., transition, main group, and lanthanide) complexes of the hydroxy-substituted texaphyrin derivatives of the present invention have unusual water solubility and stability. They absorb light strongly in a physiologically important region (i.e. 690-880 nm). They have enhanced relaxivity and therefore are useful in magnetic resonance imaging. They form long-lived triplet states in high yield and act as photosensitizers for the generation of singlet oxygen. Thus, they are useful for inactivation or destruction of human immunodeficiency virus (HIV-1), mononuclear or other cells infected with such virus as well as tumor cells.Type: GrantFiled: August 25, 1993Date of Patent: September 19, 1995Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Gregory W. Hemmi, Tarak D. Mody
-
Patent number: 5435937Abstract: Novel compounds obtainable by reacting together an imido-reagent such as diphenylphosphonimidotriphenylphosphorane) with a chelate of a transition or lanthanide or actinide metal, such as tris(dibenzoylmethide) europium III, has the property of fluorescing in UV radiation. The invention includes solid polymer bodies containing such compounds, or chelates of transition or lanthanide or actinide metals generally, the bodies having the property of emitting light by virtue of internally generated, e.g. by tritium ionising radiation. The body is preferably of polystyrene formed by polymerising the monomer in the presence of the compound or metal chelate.Type: GrantFiled: February 12, 1993Date of Patent: July 25, 1995Assignee: Amersham International plcInventors: Colin D. Bell, John H. C. Howse
-
Patent number: 5432171Abstract: The present invention involves water soluble hydroxy-substituted texaphyrins retaining lipophilicity, the synthesis of such compounds and their uses. These expanded porphyrin-like macrocycles are efficient chelators of divalent and trivalent metal ions. Various metal (e.g., transition, main group, and lanthanide) complexes of the hydroxy-substituted texaphyrin derivatives of the present invention have unusual water solubility and stability. They absorb light strongly in a physiologically important region (i.e. 690-880 nm). They have enhanced relaxivity and therefore are useful in magnetic resonance imaging. They form long-lived triplet states in high yield and act as photosensitizers for the generation of singlet oxygen. Thus, they are useful for inactivation or destruction of human immunodeficiency virus (HIV-1), mononuclear or other cells infected with such virus as well as tumor cells.Type: GrantFiled: July 28, 1993Date of Patent: July 11, 1995Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Gregory W. Hemmi, Tarak D. Mody
-
Patent number: 5424305Abstract: Purified imines of porphyrins, chlorins, bateriochlorins, chlorophylls, bacteriochlorophylls, purpurins, reduced purpurins, verdins, Diels Alder adducts, benzochlorins and metal complexes of the foregoing imines are disclosed for retarding growth of cancer tumors such as bladder tumors. The formulas of the benzochlorinimines and of the benzochlorinimine metal complexes are set forth below: ##STR1## In specific examples, M in the metal complexes is a copper cation that is complexed with two of the nitrogens of the benzochlorinimine R' and R"" are methyl, and R1 through R8 are ethyl.Type: GrantFiled: November 24, 1993Date of Patent: June 13, 1995Assignees: The University of Toledo, Medical College of OhioInventors: Dimitris Skalkos, Steven H. Selman, James A. Hampton
-
Patent number: 5374416Abstract: The invention relates to ligands of formula ##STR1## in which B represents an ##STR2## W representing the ##STR3## group, in which groups X and Z represent a heterocycle. The invention also relates to the monometallic or polymetallic complexes formed by these ligands with metal ions chosen from lanthanide ions, transition metal ions. barium, bismuth, lead and the radioisotopes .sup.99m Tc, .sup.111 In, .sup.90 Y, .sup.64 Cu and .sup.169 Yb, as well as the physiologically acceptable salts of these complexes.The salts of these complexes may be used as diagnostic or therapeutic agents in nuclear magnetic resonance imaging and X-ray radiology, as in-vivo chemical shift agents and in nuclear medicine.Type: GrantFiled: November 17, 1992Date of Patent: December 20, 1994Assignee: Guerbet S.A.Inventors: Olivier Rousseaux, Michel Schaefer, Anne Bouillot, Dominique Meyer
-
Patent number: 5371199Abstract: Porphyrins substituted with, for example, vinyl and acetylene groups are provided, along with polymers containing the same. In preferred embodiments, the substituted porphyrins are prepared by coupling halogenated porphyrins with carbon-centered anionic groups via metal-mediated crosscoupling reactions under stoichiometric or catalytic conditions.Type: GrantFiled: August 14, 1992Date of Patent: December 6, 1994Assignee: The Trustees of the University of PennsylvaniaInventors: Michael J. Therien, Stephen G. DiMagno
-
Patent number: 5346670Abstract: Red-shifted, water-soluble, fluorescent, monomerically-tetherable derivatives having the formula: ##STR1##wherein, M represents either H.sub.2 or is selected from among the following metals: aluminum, silicon, phosphorus, gallium, germanium, cadmium, scandium, magnesium, tin, and zinc. Each R.sub.1 is independently selected from --XYW, --YW, and --W. X represents either a carbon, or heteroatom selected from among oxygen, nitrogen, sulfur, phosphorus, silicon, and selenium; Y represents a linking group; and W represents a water solubilizing group. The substituent R.sub.2 is selected from among --A, --Y'A, --XA, and --XY'A, where A denotes a biological entity such as an antibody, antibody fragment, nucleotide, nucleic acid probe, antigen, oligonucleotide, deoxynucleotide, dideoxynucleotide, avidin, streptavidin or membrane probe, or R.sub.2 is a reactive or activatable group suitable for conjugating to a biological entity.Type: GrantFiled: June 8, 1992Date of Patent: September 13, 1994Assignee: British Technology Group U.S.A. Inc.Inventors: George E. Renzoni, Deborah C. Schindele, Louis J. Theodore, Clifford C. Leznoff, Karen L. Fearon, Barry V. Pepich
-
Patent number: 5344948Abstract: Neutral single-source molecular organic precursors containing tetradentate tripodal chelating ligands are provided that are useful for the preparation of films using chemical vapor deposition. These complexes can be generally represented by the formula ##STR1## wherein "M" is selected from the group consisting of a lanthanide, an actinide, a Group IIIA metal, a Group IIIA metalloid, a Group IVA metal, a Group IVA metalloid, a Group VA metal, a Group VA metalloid, a Group IIIB metal, a Group IVB metal, a Group VB metal, a Group VIB metal, a Group VIIB metal, and a Group VIIIB metal. The ligand "Z" can be present or absent, i.e., k=0-1, and is selected from the group consisting of hydrogen, halide, and a group bonded to "M" through N, O, P, S, As, Si, or C. In the tetradentate tripodal chelating ligand "E.sub.c " is N, P, or As, and m=0-1. When "E.sub.t " is N, P, or As, m=1, and when "E.sub.t " is O, S, or Se, m=0. Each "R.sup.1 " is independently selected from the group consisting of hydrogen, (C.sub.1 -C.Type: GrantFiled: July 10, 1992Date of Patent: September 6, 1994Assignee: Iowa State University Research Foundation, Inc.Inventor: John G. Verkade
-
Patent number: 5319121Abstract: A method is provided for preparing preceramic polymers and and silicious ceramic materials which derive therefrom. The preceramic polymers are polysiloxanes which are synthesized by catalytically activating Si--H bonds in a hydridosiloxane starting material and replacing the activated hydrogen atoms with non-hydrogen substituents. These preceramic polysiloxanes are pyrolyzed in a selected atmosphere to give the desired ceramic product. Ceramic products which may be prepared by this technique include silica, silicon oxynitride, silicon carbide, and metal silicates.Type: GrantFiled: July 2, 1992Date of Patent: June 7, 1994Assignee: SRI InternationalInventor: Yigal Blum
-
Patent number: 5256383Abstract: The invention relates to a process for the separation of actinides from lanthanides by the selective extraction of the actinides in an organic solvent incorporating a propane diamide.This process consists of adding to the aqueous nitric solution containing the actinides and lanthanides a thiocyanate, e.g. ammonium thiocyanate, followed by the contacting of said solution with an organic solvent incorporating at least one propane diamide, e.g. 2-tetradecyl-N,N'-dimethyl-N,N'-dibutyl-propane diamide and optionally a quaternary ammonium salt such as trilauryl methyl ammonium (TMA) thiocyanate or a mixture of quaternary ammonium thiocyanates.This leads to distribution coefficients D.sub.M for the actinides (Am) and the lanthanides (Eu, Ce) making it possible to achieve high actinide/lanthanide separation factors.Type: GrantFiled: August 13, 1992Date of Patent: October 26, 1993Assignee: Commissariat a l'Energie AtomiqueInventors: Pierres-Yves Cordier, Christine Cuillierdier, Claude Musikas
-
Patent number: 5252720Type: GrantFiled: January 21, 1992Date of Patent: October 12, 1993Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Gregory W. Hemmi, Tarak D. Mody
-
Patent number: 5250668Abstract: A family of benzochlorins, a family of verdins, a family of porphyrin derivatives and metal complexes thereof are disclosed. The benzochlorins have the formula of FIG. 3 of the attached drawings; their metal complexes have the formula of FIG. 1 . The verdins have the formulas of FIGS. 4 and 6 of the attached drawings; their metal complexes have the formulas of FIGS. 2 and 5. The porphyrin derivatives have the formula of FIG. 9 of the attached drawings; their metal complexes have the formula of FIG. 10 . Solutions of the benzochlorins, verdins, porphyrin derivatives and metal complexes which are physiologically acceptable for intravenous administration are also disclosed, as are emulsions or suspensions of the solutions, and compositions which additionally include cyclodextrin, and wherein the molecules of the benzochlorin, verdin, porphyrin derivative or metal complex are encapsulated within the molecules of the cyclodextrin.Type: GrantFiled: January 8, 1992Date of Patent: October 5, 1993Inventors: Alan R. Morgan, Steven H. Selman
-
Patent number: 5246901Abstract: This invention provides novel compositions comprising aryl phosphonic or phosphinic acids substituted with more than one sulfo radical. These novel compounds may be reacted with tetravalent metal ions to provide polymers having an inorganic backbone, which polymers are useful as acid catalysts.Type: GrantFiled: May 23, 1988Date of Patent: September 21, 1993Assignee: Catalytica, Inc.Inventor: William A. Sanderson
-
Patent number: 5206346Abstract: Materials are labelled with a radioisotope by passing them through a column packed with (a) beads coated with an oxidizing reagent for coupling the radioisotopes to the materials, (b) as anion resin, and (c) a material for trapping elemental isotope, and flowing a mixture of the radioisotope and a solution of the material to be labelled through the column.Type: GrantFiled: December 5, 1990Date of Patent: April 27, 1993Assignee: E. I. Du Pont de Nemours and CompanyInventor: William R. Taylor
-
Patent number: 5166324Abstract: A compound of the formula MX.sub.n L.sub.m wherein M is a metal atom selected from the group consisting of thorium, plutonium, neptunium or americium, X is a halide atom, n is an integer selected from the group of three or four, L is a coordinating ligand selected from the group consisting of aprotic Lewis bases having an oxygen-, nitrogen-, sulfur-, or phosphorus-donor, and m is an integer selected from the group of three or four for monodentate ligands or is the integer two for bidentate ligands, where the sum of n+m equals seven or eight for monodentate ligands or five or six for bidentate ligands, a compound of the formula MX.sub.n wherein M, X, and n are as previously defined, and a process of preparing such actinide metal compounds including admixing the actinide metal in an aprotic Lewis base as a coordinating solvent in the presence of a halogen-containing oxidant, are provided.Type: GrantFiled: February 7, 1991Date of Patent: November 24, 1992Assignee: The United States of America as represented by the United States Department of EnergyInventors: Larry R. Avens, Bill D. Zwick, Alfred P. Sattelberger, David L. Clark, John G. Watkin
-
Patent number: 5128494Abstract: A method is provided for preparing preceramic polymers and silicious ceramic materials which derive therefrom. The preceramic polymers are polysiloxanes which are synthesized by catalytically activating Si-H bonds in a hydridosiloxane starting material and replacing the activated hydrogen atoms with non-hydrogen substituents. These preceramic polysiloxanes are pyrolyzed in a selected atmosphere to give the desired ceramic product. Ceramic products which may be prepared by this technique include silica, silicon oxynitride, silicon carbide, and metal silicates.Type: GrantFiled: April 21, 1989Date of Patent: July 7, 1992Assignee: SRI InternationalInventor: Yigal Blum
-
Patent number: 5109129Abstract: A family of benzochlorins, a family of verdins, a family of porphyrin derivatives and metal complexes thereof are disclosed. the benzochlorins have the formula of FIG. 3 of the attached drawings; their metal complexes have the formula of FIG. 1. The verdins have the formula of FIG. 4 of the attached drawings; their metal complexes have the formula of FIG. 2. The porphyrin derivatives have the formula of FIG. 9 of the attached drawings; their metal complexes have the formula of FIG. 10. Solutions of the benzochlorins, verdins, porphyrin derivatives and metal complexes which are physiologically acceptable for intravenous administration are also disclosed, as are emulsions or suspensions of the solutions, and compositions which additionally include cyclodextrin, and wherein the molecules of the benzochlorin, verdin, prophyrin derivative or metal complex are encapsulated within the molecules of the cyclodextrin. The solvent for the solutions can be a product of the reaction of ethylene oxide with castor oil.Type: GrantFiled: August 3, 1990Date of Patent: April 28, 1992Assignee: The University of Toledo, Medical College of OhioInventors: Alan R. Morgan, Steven H. Selman
-
Patent number: 5082955Abstract: A method for separating the isomers of a crown ether compound and making it possible to recover in particular the pure cis-syn-cis isomer from DCH 18C6 includes:a) dissolving in an organic solvent a mixture of the isomers of said crown compound including the cis-anti-cis isomer and the cis-syn-cis isomer,b) adding uranyl nitrate to the solution obtained in stage a) in sufficient quantities so that virtually all of the isomers, except the cis-syn-cis isomer, are precipitated in the form of complexes with the uranyl nitrate,c) separating the formed precipitate,d) recovering the cis-syn-cis isomer from the solution, ande) recovering the cis-anti-cis isomer from the precipitate.Type: GrantFiled: December 11, 1990Date of Patent: January 21, 1992Assignee: Cogema-Compagnie Generale Des Matieres NucleariresInventors: Marc Lemaire, Alain Guy, Jacques Foos, Vincent Guyon, Rodolphe Chomel
-
Patent number: 5081231Abstract: Novel di(poly-substituted cyclopentadienyl)-allylic uranium complexes can be employed to catalyze the dimerization of propylene to form 4-methyl-1-pentene selectively. The novel catalyst complexes can be prepared from novel di(poly-substituted cyclopentadienyl)-U(IV) monohalo monoallylic complexes.Type: GrantFiled: January 16, 1990Date of Patent: January 14, 1992Assignee: The Dow Chemical CompanyInventors: James C. Stevens, William A. Fordyce
-
Patent number: 5079378Abstract: A highcarbon-containing diaryliodonium initiator for cationic polymerization which possesses enhanced solubility characteristics over conventional diaryliodonium initiators. By the disclosed process, a novel photo/thermal initiator is obtained which is uniquely characterized by the concatenation of a long chain ester with an aryl group, resulting in a total number of carbon atoms in the entire moiety attached to the iodine atom in excess of 20.Type: GrantFiled: July 27, 1990Date of Patent: January 7, 1992Assignee: Polyset CorporationInventor: James V. Crivello
-
Patent number: 5061476Abstract: Radiolabeled colloid compositions and a method for the preparation of radionuclide-colloid compositions useful in the treatment of rheumatoid arthritis are disclosed. A radionuclide selected from the group consisting of Sm-135, Ho-166, In-155m, Y-90, Gd-159 La-140, Lu-177, or Yb-175 is sorbed to a previously prepared iron-hydroxide colloid. The radiolabeled colloid compositions are comprised of spherical aggregations containing greater than 50% of the radioactive metal in iron-hydroxide particles. The method produces stable radionuclide iron-hydroxide compositions which are useful in therapeutic procedures such as radiation synovectomy.Type: GrantFiled: December 27, 1989Date of Patent: October 29, 1991Assignee: The Dow Chemical CompanyInventors: Jaime Simon, Lance A. Cooper, Kenneth McMillan, David A. Wilson
-
Patent number: 5043101Abstract: This invention provides particle compositions possessing ferromagnetic, paramagnetic or diamagnetic properties. The particles are especially useful when used in the disease diagnostic and treatment regimens as described in U.S. Pat. Nos. 4,106,448, 4,136,683 and 4,303,636.Type: GrantFiled: March 29, 1988Date of Patent: August 27, 1991Inventor: Robert T. Gordon
-
Patent number: 5021556Abstract: Chelating compounds which comprise one or more sulfur atoms and are to be radiolabeled with metal radionuclides to form the corresponding chelates are disclosed. The chelating compounds comprise thioacetal or hemithioacetal sulfur protecting groups which are displaced during the radiolabeling reaction, which is conducted at acidic pH, such that bonds form between said sulfur atoms and said radionuclide. The resulting metal radionuclide chelates have diagnostic and therapeutic medical uses.Type: GrantFiled: July 1, 1988Date of Patent: June 4, 1991Assignee: NeoRx CorporationInventor: Ananthachari Srinivasan
-
Patent number: 5006643Abstract: The present invention is directed to a novel process for preparing isothiocyanate functionalized chelates by reacting amino functionalized chelates with thiophosgene.Type: GrantFiled: July 20, 1989Date of Patent: April 9, 1991Assignee: The Dow Chemical CompanyInventors: Michael J. Fazio, Douglas K. Pollock, Nicolas J. Kotite
-
Patent number: 4988808Abstract: A family of benzochlorins, a family of verdins, a family of porphyrin derivatives and metal complexes thereof are disclosed. The benzochlorins have the formula of FIG. 3 of the attached drawings; their metal complexes have the formula of FIG. 1. The verdins have the formula of FIG. 4 of the attached drawings; their metal complexes have the formula of FIG. 2. The porphyrin derivatives have the formula of FIG. 9 of the attached drawings; their metal complexes have the formula of FIG. 10. Solutions of the benzochlorins, verdins, porphyrin derivatives and metal complexes which are physiologically acceptable for intravenous administration are also disclosed, as are emulsions or suspensions of the solutions, and compositions which additionally include cyclodextrin, and wherein the molecules of the benzochlorin, verdin, porphyrin derivatives or metal complex are encapsulated within the molecules of the cyclodextrin. The solvent for the solutions can be a product of the reaction of ethylene oxide with castor oil.Type: GrantFiled: December 11, 1989Date of Patent: January 29, 1991Assignees: The University of Toledo, Medical College of OhioInventors: Alan R. Morgan, Steven H. Selman
-
Patent number: 4987227Abstract: A 13 or 14 member macrocyclic compound having the following ring nucleus: ##STR1##This work was supported by grants from the National Institutes of Health (GM-34841) and the National Science Foundation (CHE-8706616).Type: GrantFiled: February 23, 1990Date of Patent: January 22, 1991Assignee: The Research Foundation of State University of New YorkInventors: Cynthia Burrows, Heungsik Yoon, Thomas R. Wagler
-
Patent number: 4960869Abstract: Novel di(poly-substituted cyclopentadienyl)-allylic uranium complexes can be employed to catalyze the dimerization of propylene to form 4-methyl-1-pentene selectively. The novel catalyst complexes can be prepared from novel di(poly-substituted cyclopentadienyl)-U-(IV) monohalo monoallylic complexes.Type: GrantFiled: August 1, 1988Date of Patent: October 2, 1990Assignee: The Dow Chemical CompanyInventors: James C. Stevens, William A. Fordyce